{"product_id":"skhb-five-forces-analysis","title":"Shanghai Kehua Bio-engineering Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eShanghai Kehua Bio-engineering faces moderate supplier power and high regulatory scrutiny, while buyer power and rivalry intensify amid pricing pressure and innovation cycles; barriers to entry are notable but niche biotech startups pose targeted threats.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Shanghai Kehua Bio-engineering’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Raw Material Dependency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShanghai Kehua Bio-engineering depends on high-purity antigens and enzymes from global suppliers—about 60–70% of its critical reagent spend in 2024—so supplier influence is material. Domestic suppliers rose to ~35% market share in 2024, but switching needs months of validation and can trigger CFDA\/NMPA re-filing, raising costs ~10–15% and delaying revenue recognition. That makes supplier power moderate but strategically significant.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Instrumentation Component Sourcing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe manufacturing of automated diagnostic instruments relies on precise optical and electronic parts made by few specialized firms, giving suppliers pricing and delivery leverage; industry data shows the top 5 global precision optics suppliers control ~60% of market share as of 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier Concentration in Biotech\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe upstream market for critical diagnostic inputs is dominated by a few global biotech giants—Thermo Fisher Scientific, Danaher, and Roche together held about 45% of the global reagents and consumables market in 2024—reducing alternative suppliers for specialized reagents used in blood screening and tumor marker assays.\u003c\/p\u003e\n\u003cp\u003eThis concentration raises supply-chain risk for Shanghai Kehua Bio-engineering: a 10–20% price rise or a strategic shift by a dominant supplier could raise COGS by roughly 3–6 percentage points, given reagent costs represented ~18% of product costs in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnological Proprietary Inputs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProprietary reagents and biomarkers used in molecular diagnostics are often patent‑protected by third‑party suppliers, locking Shanghai Kehua Bio-engineering into higher input costs and licensing fees; for example, global assay reagent royalties average 8–12% of product price in 2024, raising COGS for new molecular lines.\u003c\/p\u003e\n\u003cp\u003eReplacing these inputs needs major R\u0026amp;D or licensing—Kehua would face multi‑year development and likely $5–15M per assay to validate substitutes—so supplier leverage intensifies as molecular revenue grows.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatents raise switching cost and licensing fees (8–12% typical royalty, 2024)\u003c\/li\u003e\n\u003cli\u003eSubstitute development ≈ $5–15M and 12–24 months per assay\u003c\/li\u003e\n\u003cli\u003eDependency strongest for high‑growth molecular products\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising Costs of Specialized Labor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSuppliers of specialized research services and high-tech equipment face 12–18% higher average salaries for biotechnologists and engineers in Shanghai from 2020–2024, pushing service fees up 8–12% for diagnostic firms like Shanghai Kehua Bio-engineering.\u003c\/p\u003e\n\u003cp\u003eAs automation adoption rises—estimated 22% capex growth in biotech manufacturing 2021–2024—reliance on these suppliers increases, concentrating supplier power and raising switching costs for diagnostics firms.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSalary increase: 12–18% (2020–2024)\u003c\/li\u003e\n\u003cli\u003eService fee pass-through: +8–12%\u003c\/li\u003e\n\u003cli\u003eBiotech automation capex growth: ~22% (2021–2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh supplier leverage: concentrated reagents, costly switches raise COGS vulnerability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold moderate-to-high power: critical reagents made up ~60–70% of reagent spend in 2024, top 3 suppliers held ~45% global share (2024), and switching costs (validation, NMPA re-filing) add ~10–15% to costs; COGS sensitivity: a 10–20% input price rise would raise COGS ~3–6 pts. Substitution R\u0026amp;D ~ $5–15M and 12–24 months per assay, royalties 8–12% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eReagent spend concentration (2024)\u003c\/td\u003e\n\u003ctd\u003e60–70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop 3 suppliers market share (2024)\u003c\/td\u003e\n\u003ctd\u003e≈45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSwitching cost impact\u003c\/td\u003e\n\u003ctd\u003e+10–15% cost, 12–24m delay\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubstitute R\u0026amp;D per assay\u003c\/td\u003e\n\u003ctd\u003e$5–15M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalty range (2024)\u003c\/td\u003e\n\u003ctd\u003e8–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS sensitivity\u003c\/td\u003e\n\u003ctd\u003e+3–6 pts if input +10–20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored exclusively for Shanghai Kehua Bio-engineering, this Porter's Five Forces overview uncovers competitive drivers, buyer\/supplier power, entry barriers, substitutes, and disruptive threats that shape its pricing, profitability, and strategic positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCompact Porter's Five Forces snapshot for Shanghai Kehua Bio-engineering—instantly highlights supplier, buyer, competitor, entrant, and substitute pressures to speed strategic decisions and investor briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCentralized Government Procurement Policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Chinese Volume-Based Procurement (VBP) centralizes buying for public hospitals, shifting pricing power to state health authorities; in 2024 VBP covered over 50% of hospital procurements and cut diagnostics prices by 20–40% in pilot categories. Shanghai Kehua must compete on thin margins to win large tenders, where single contracts can represent 30–60% of annual public-sales for a product line.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital System Consolidation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHospital system consolidation in China has raised buyer power: by 2024 over 60% of tertiary hospitals belonged to regional clusters that centralize procurement, pushing Shanghai Kehua Bio-engineering to compete on bundled offers for reagents, instruments, and service to win contracts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow Switching Costs for Reagents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiagnostic instruments cost millions up front, but 70–80% of lifecycle revenue comes from reagents, so buyers push for open-system compatibility and lower reagent prices; in China, hospitals switching to cheaper reagents cut supplier margins by 5–15% in 2024 according to industry reports. Commoditization of common infectious-disease assays (e.g., PCR panels) and competitors offering 10–30% cheaper or more accurate reagents increase buyer leverage, forcing frequent price concessions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDemand for Integrated Diagnostic Value\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eModern clinical labs now demand integrated diagnostic value: products plus digital data integration and 24\/7 rapid technical support, not standalone reagents or instruments.\u003c\/p\u003e\n\u003cp\u003eCustomers leverage these service needs in negotiations—global IVD service contracts grew 14% in 2024, so buyers press for bundled pricing and SLAs to lower total cost of ownership.\u003c\/p\u003e\n\u003cp\u003eShanghai Kehua must keep enhancing cloud interfaces, remote diagnostics, and training to justify premium pricing in a buyer-centric market; otherwise margin pressure rises.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eService-led deals rose 14% in 2024\u003c\/li\u003e\n\u003cli\u003eBuyers seek SLAs, data integration, 24\/7 support\u003c\/li\u003e\n\u003cli\u003eKehua needs cloud, remote diag, training to protect margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInformation Transparency in Healthcare\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRising digital transparency in diagnostics—price databases and performance registries—lets hospital procurement compare Shanghai Kehua Bio-engineering to peers; a 2024 IQVIA report showed 28% of Chinese hospitals use online price benchmarking, cutting information asymmetry and boosting buyer leverage.\u003c\/p\u003e\n\u003cp\u003eThat shifts negotiations toward demonstrated clinical utility; Kehua must prove superior outcomes or workflow gains to command premium over lower-cost rivals.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003e28% of hospitals use price benchmarking (IQVIA 2024)\u003c\/li\u003e\n\u003cli\u003eTransparency reduces supplier information edge\u003c\/li\u003e\n\u003cli\u003eFocus: unique clinical outcomes, workflow value\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyers' VBP grip slashes prices 20–40%—Kehua pivots to bundled outcomes, cloud \u0026amp; SLAs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyers hold strong leverage: 2024 VBP covered \u0026gt;50% hospital spend and cut prices 20–40%; 60% of tertiary hospitals in clusters centralize procurement; reagents drive 70–80% lifecycle revenue so buyers extract 5–15% margin cuts; service-led contracts rose 14% and 28% of hospitals use price benchmarking (IQVIA 2024), forcing Kehua to sell bundled outcomes, cloud, and SLAs to protect margins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVBP hospital spend\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTertiary hospital clusters\u003c\/td\u003e\n\u003ctd\u003e60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReagent share of lifecycle rev\u003c\/td\u003e\n\u003ctd\u003e70–80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice cuts from VBP\u003c\/td\u003e\n\u003ctd\u003e20–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService-led contract growth\u003c\/td\u003e\n\u003ctd\u003e14%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals using benchmarking\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eShanghai Kehua Bio-engineering Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Porter’s Five Forces analysis of Shanghai Kehua Bio-engineering you'll receive immediately after purchase—no placeholders or mockups, fully formatted and ready for use. The document covers supplier power, buyer power, competitive rivalry, threat of substitutes, and barriers to entry with actionable insights tailored to industry specifics. Once you buy, you’ll get this exact file for immediate download.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747556635001,"sku":"skhb-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/skhb-five-forces-analysis.png?v=1772199789","url":"https:\/\/matrixbcg.com\/products\/skhb-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}